Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing antibodies against IL1RAP (CAN04 and CAN10). CAN04 is being studied in a Phase I/IIa CANFOUR in solid tumours, while CAN10 is a preclinical project in inflammatory diseases.
Cantargia is developing antibodies against IL1RAP. In December 2019, the company reported interim data from the ongoing three-arm Phase IIa study with CAN04 (targets IL-1 signalling pathway) in combination with first-line chemotherapy in NSCLC and pancreatic cancer. 4/7 evaluable pancreatic cancer patients achieved partial response and 2/3 evaluable NSLC patients achieved an objective response (one complete and one partial response). The results compare favourably to historical response rates to standalone chemotherapy regimens (23% in PDAC; 22–28% in first-line NSCLC). More interim data will be presented in 2020, while final efficacy data are expected in 2021. Cantargia also plans to initiate a Phase Ib trial in the US with CAN04 in combination with a checkpoint inhibitor. Recently, Cantargia introduced CAN10, a preclinical project in inflammation uniquely targeting three interleukin pathways, IL-1, IL-33 and IL-36.
Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in oncology.